| radium-223 | |
|---|---|
| Name | Radium-223 |
| Mass number | 223 |
| Atomic number | 88 |
| Half life | 11.43 d |
| Decay modes | Alpha decay |
| Decay products | radon-219 → polonium-215 |
| Natural abundance | Trace, produced synthetically |
| Discovered | 1900s (isotopic identification) |
radium-223
Radium-223 is a radioactive isotope of radium notable for its short half-life and predominant alpha decay mode. In the context of Quantum Physics it provides an experimentally accessible system for studying quantum tunnelling, nuclear structure, and alpha-particle formation, and it has practical importance as a targeted radiopharmaceutical for bone metastases.
^223Ra has atomic number 88 and mass number 223. Its measured half-life is about 11.43 days and it decays primarily by emission of alpha particles to produce radon-219, initiating a short decay chain through isotopes such as polonium-215 and lead-211. Nuclear properties of interest include its alpha decay energy (Qα), nuclear spin and parity assignments, and branching ratios, all of which are determined by experimental nuclear spectroscopy at facilities such as the CERN ISOLDE facility, Oak Ridge National Laboratory, and national nuclear data centers like the International Atomic Energy Agency (IAEA) Nuclear Data Section. Precise mass measurements and decay schemes are catalogued in evaluated data sets such as the Evaluated Nuclear Structure Data File.
^223Ra is produced both as a decay product in generator systems and via neutron activation or charged-particle reactions in research reactors and cyclotrons. Generator-based production uses parent isotopes such as actinium-227 in a ^227Ac→^223Ra generator, an approach employed by commercial suppliers and medical manufacturers like Bayer AG for radiopharmaceutical supply chains. Alternative production routes include proton irradiation of suitable targets at accelerator facilities (e.g., TRIUMF, Paul Scherrer Institute) and neutron capture pathways in research reactors (e.g., High Flux Isotope Reactor). Decay proceeds by emission of an alpha particle whose production is described microscopically by preformation of an alpha cluster and quantum tunnelling through the Coulomb barrier, with daughter recoils and gamma emissions important for dosimetry and detection.
Radium-223 is an archetypal nucleus for exploring quantum-mechanical models of alpha decay. The process is typically modeled using the Gamow theory of alpha decay and subsequently refined by cluster models, shell-model calculations, and semiclassical Wentzel–Kramers–Brillouin (WKB) approximations to calculate tunnelling probabilities. Studies involve input from mean-field theories like the Hartree–Fock and Density functional theory approaches tailored for nuclear matter, and ab initio techniques where computationally feasible. Experimental observables—alpha energies, lifetimes, reduced widths, and angular correlations—constrain theoretical descriptions of alpha preformation factors and shape coexistence in heavy nuclei. Investigations often occur within collaborations linking experimental groups (e.g., GSI Helmholtz Centre for Heavy Ion Research, Lawrence Berkeley National Laboratory) and theoretical groups focused on nuclear many-body problems and applications of quantum tunnelling.
Radium-223 dichloride is approved as a radiopharmaceutical for the treatment of castration-resistant prostate cancer with symptomatic bone metastases due to its alpha-emitter properties and high linear energy transfer. Clinical development involved randomized trials coordinated by academic oncology groups and pharmaceutical companies, informed by regulators such as the European Medicines Agency and the U.S. Food and Drug Administration. The short range of emitted alpha particles concentrates dose within millimetres of bone surfaces, reducing systemic exposure compared with beta emitters. Dosimetry models integrate radiobiology, microdosimetry, and stochastic track structure simulations developed in the field of radiation physics and medical physics groups at institutions like Memorial Sloan Kettering Cancer Center and university hospitals.
Handling ^223Ra requires controls consistent with alpha-emitting radionuclides: sealed-source techniques, gloveboxes or hot cells, and contamination monitoring. Radiological protection principles from the International Commission on Radiological Protection (ICRP) guide occupational dose limits, intake assessment, and bioassay protocols. Because alpha particles deliver high local dose but are easily shielded by modest materials, emphasis is on preventing ingestion or inhalation; protocols developed by national regulators and hospital radiation safety offices specify engineering controls, personal protective equipment, and waste management practices. Emergency procedures follow standards promulgated by organizations such as World Health Organization and national nuclear regulatory bodies.
Detection of ^223Ra and its decay products employs alpha spectroscopy, liquid scintillation counting, and gamma spectroscopy for coincident gamma emissions in the decay chain. Surface contamination monitors and solid-state detectors (e.g., silicon semiconductor detectors) are used for alpha spectrometry, while high-purity germanium detectors characterize gamma lines for assay and quality control. Accelerator mass spectrometry and radiochemical separation techniques are used for trace-level measurements in environmental and biological samples. Instrumentation development often involves collaborations between metrology institutes such as National Institute of Standards and Technology (NIST) and specialized manufacturers.
Regulation of ^223Ra production, transport, medical use, and disposal is governed by international conventions and national laws administered by agencies such as the International Atomic Energy Agency, the U.S. Nuclear Regulatory Commission, and national health ministries. Environmental assessments address potential release pathways from production facilities and medical waste; modeling of radionuclide transport integrates radioecology and radiation protection science. Licensed use in medicine requires compliance with pharmacovigilance, good manufacturing practice (GMP) for radiopharmaceuticals, and post-marketing surveillance coordinated with hospital radiation safety programs and national regulators.
Category:Isotopes of radium Category:Alpha-emitting radioisotopes